Investigational Drug Information for LOU064
✉ Email this page to a colleague
What is the development status for investigational drug LOU064?
LOU064 is an investigational drug.
There have been 21 clinical trials for LOU064.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 20th 2025.
The most common disease conditions in clinical trials are Urticaria, Chronic Urticaria, and Dermatitis. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].
There are fifty-two US patents protecting this investigational drug and three hundred and four international patents.
Summary for LOU064
| US Patents | 52 |
| International Patents | 304 |
| US Patent Applications | 213 |
| WIPO Patent Applications | 105 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 2 (2025-03-20) |
| Vendors | 44 |
Recent Clinical Trials for LOU064
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants. | Novartis Pharmaceuticals | PHASE1 |
| Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria | Novartis Pharmaceuticals | PHASE2 |
| Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa | Novartis Pharmaceuticals | PHASE3 |
Clinical Trial Summary for LOU064
Top disease conditions for LOU064
Top clinical trial sponsors for LOU064
US Patents for LOU064
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LOU064 | ⤷ Start Trial | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Start Trial |
| LOU064 | ⤷ Start Trial | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Start Trial |
| LOU064 | ⤷ Start Trial | Amino pyrimidine derivatives | Novartis AG | ⤷ Start Trial |
| LOU064 | ⤷ Start Trial | Treatment of cancer using a CLL-1 chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LOU064
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LOU064 | Argentina | AR102035 | 2034-07-21 | ⤷ Start Trial |
| LOU064 | Australia | AU2015292744 | 2034-07-21 | ⤷ Start Trial |
| LOU064 | Australia | AU2020202726 | 2034-07-21 | ⤷ Start Trial |
| LOU064 | Brazil | BR112017001183 | 2034-07-21 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
